Back

The Drug-Induced Respiratory Disease Website and App

XV.f

XV - Pathology

Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

Last update 05/03/2014

Hyaline membranes and resolving alveolar damage are suggestive if not hallmarks

Causative drugs

58

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

Alemtuzumab
I.a
I.b
II.a
II.b
III.a
IV.a
VI.b
X.e
X.g
X.k
X.ac
X.an
XIII.b
XV.a
XV.f
XVII.b
XVII.e
XVII.h
XVII.m
Amantadine
II.a
II.b
XII.m
XV.f
Amiodarone
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.h
I.k
I.l
I.s
I.u
I.w
I.z
I.aa
I.ao
I.at
I.ax
I.ay
II.b
II.l
III.a
III.c
IV.a
IV.d
IV.r
V.a
V.c
V.d
V.t
VI.a
VI.i
VIII.a
IX.a
IX.d
IX.ai
X.d
X.f
X.q
XI.c
XI.f
XII.a
XII.c
XII.e
XII.l
XII.n
XII.p
XII.t
XII.af
XII.au
XV.a
XV.b
XV.c
XV.d
XV.f
XV.g
XV.h
XV.i
XV.j
XV.k
XV.m
XV.o
XV.r
XV.ao
XV.bt
XV.co
XV.dc
XVI.b
XVI.i
XVI.j
XVI.n
XVI.s
XVI.w
XVI.aa
XVI.ab
XVI.ay
XVI.az
XVI.bj
XVI.bq
XVI.bt
XVI.bx
XVI.ca
XVII.e
XVIII.b
XVIII.j
XVIII.k
XVIII.p
XIX.a
XIX.b
XIX.c
XIX.e
XIX.f
XIX.m
XIX.p
XXVIII.c
Antiviral therapy/agents (direct-acting) against hepatitis C virus
I.a
I.b
II.b
III.a
IV.d
V.a
X.e
XI.c
XV.f
XVI.b
XVII.f
XIX.a
XIX.b
XIX.c
Aspirin (Salicylate-ASA) - Aspirin containing drugs
I.a
I.c
I.l
II.a
II.b
III.a
III.c
III.m
IV.a
IV.f
V.e
VII.b
VIII.a
VIII.y
X.a
X.f
X.h
X.m
X.q
X.u
XI.b
XI.d
XI.ao
XI.at
XII.n
XII.s
XII.af
XV.a
XV.f
XV.w
Azathioprine
I.a
I.b
I.c
I.d
I.g
I.l
I.m
I.q
I.ah
II.b
III.a
VIII.a
X.g
X.o
XII.h
XIII.b
XV.a
XV.e
XV.f
XV.j
XV.bq
XVII.e
XVII.h
XIX.a
BCG therapy (topical instillations in the urinary bladder)
I.a
I.b
I.c
I.l
I.m
II.b
IV.d
V.a
VII.a
VII.e
VIII.c
IX.r
IX.ab
X.g
X.l
X.m
X.u
XV.e
XV.f
XV.ba
XV.cg
XVI.u
XVI.ai
XVII.f
XVII.i
XIX.a
Bleomycin
I.a
I.b
I.c
I.d
I.f
I.g
I.k
I.l
I.p
I.v
I.w
II.b
II.t
V.f
V.p
V.z
VI.c
VI.f
VII.e
VII.h
XI.b
XI.c
XV.a
XV.b
XV.c
XV.d
XV.f
XV.h
XV.i
XV.j
XV.l
XV.ax
XV.be
XV.bf
XVI.a
XVI.b
XVI.e
XVI.k
XVI.w
XVI.ab
XVI.af
XVI.bl
XVIII.j
XIX.b
XXIV.a
XXIV.b
Busulfan
I.a
I.b
I.d
I.g
I.l
I.n
I.v
II.b
VI.b
XV.a
XV.c
XV.d
XV.f
XV.h
XV.i
XV.n
XV.bc
XVI.d
XVII.f
XIX.g
Carmustine (BCNU)
I.a
I.b
I.g
I.l
I.x
I.ad
II.a
II.b
V.a
V.f
V.m
V.ab
XII.c
XV.a
XV.f
XV.h
XV.i
XV.ap
XVI.a
XVI.b
XVI.m
Cetuximab
I.a
I.b
I.d
I.l
II.b
X.f
X.g
XII.m
XV.c
XV.f
Chemotherapy, antineoplastic
I.a
I.b
I.c
I.d
I.f
I.g
I.h
I.k
I.l
I.m
I.n
I.v
I.w
I.x
I.y
I.aa
I.ad
I.ao
I.au
II.a
II.b
II.c
II.d
III.a
IV.a
IV.k
V.a
V.f
V.ab
VI.b
VI.c
VI.f
VII.a
VII.h
VIII.a
VIII.t
IX.f
IX.j
IX.o
X.c
X.d
X.f
X.g
X.k
X.n
XI.b
XI.k
XI.s
XII.a
XII.b
XII.c
XII.e
XII.f
XII.g
XII.l
XII.s
XII.ai
XII.bl
XIII.a
XIII.b
XIII.d
XV.c
XV.d
XV.f
XV.i
XV.l
XV.ak
XV.am
XV.ba
XVI.ab
XVI.af
XVI.bf
XVI.bl
XVI.bw
XVII.b
XVII.c
XVII.e
XVII.g
XVII.j
XVII.r
XVII.af
XIX.g
Crizotinib
I.a
I.b
I.d
II.b
III.a
III.h
V.f
VIII.a
X.g
XI.s
XII.ag
XII.ai
XV.a
XV.c
XV.f
XVI.af
XIX.a
Cyclophosphamide
I.a
I.b
I.d
I.g
I.l
I.x
I.aa
II.a
II.b
III.a
IV.a
V.a
V.b
V.c
V.f
VI.c
IX.f
X.f
XI.b
XI.c
XI.l
XII.a
XII.c
XII.f
XII.g
XII.s
XV.a
XV.c
XV.f
XV.h
XV.i
XV.ak
XV.ap
XVI.ap
XVI.bl
XVII.b
XVII.e
XVII.q
XIX.a
Cytosine arabinoside - Aracytine - Cytarabine - Ara-C
I.a
I.d
I.k
I.l
II.a
II.b
III.a
V.i
V.m
X.c
X.o
XII.c
XII.e
XV.f
XVI.v
XVII.e
XXIV.a
Loading more…